Edition:
United States

Geron Corp (GERN.O)

GERN.O on Nasdaq

2.01USD
2 Dec 2016
Change (% chg)

$0.05 (+2.55%)
Prev Close
$1.96
Open
$1.96
Day's High
$2.04
Day's Low
$1.96
Volume
727,954
Avg. Vol
1,690,706
52-wk High
$5.30
52-wk Low
$1.81

GERN.O

Chart for GERN.O

About

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for... (more)

Overall

Beta: 2.99
Market Cap(Mil.): $348.53
Shares Outstanding(Mil.): 159.15
Dividend: --
Yield (%): --

Financials

  GERN.O Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -0.19 -- --
ROI: -21.33 -1.09 14.95
ROE: -21.33 -2.39 16.29

BRIEF-Geron Corp reports loss per share of $0.02

* Geron Corporation reports third quarter 2016 financial results and recent events

Nov 03 2016

BRIEF-Geron Corp and Janssen Pharmaceuticals enter into a license agreement

* On September 15, 2016, co, Janssen Pharmaceuticals Inc entered into a license agreement - SEC filing

Sep 19 2016

BRIEF-Geron Corp Q2 loss per share $0.05

* Geron corporation reports second quarter 2016 financial results and recent events

Aug 03 2016

BRIEF-Geron announces issuance of U.S. patents related to Imetelstat

* Geron announces issuance of U.S. patents related to Imetelstat

Jul 13 2016

Competitors

Earnings vs. Estimates